Regis C.
- Country
- France
- Department
- Hématologie et thérapie cellulaire
Research Overview
- Phase 1 Dose-Determining Study of EXS73565 in Patients with Relapsed or Refractory B-Cell Malignancies Including CLL, MCL, DLBCL, FL, and MZL
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Data & Insights
Has run more than one trial at 174 of 339 partner sites.
Specializations
Lymphoma Research
Specializes in innovative treatments for B-cell lymphomas, with particular focus on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Conducts research on novel therapeutic approaches including targeted antibody treatments and combination therapies.
- B-cell specific therapies
- CD20-expressing lymphomas
- Combination immunotherapy approaches
Leukemia Studies
Focuses on advancing treatment options for acute myeloid leukemia (AML), investigating both newly diagnosed and relapsed/refractory cases. Explores innovative therapeutic combinations and targeted approaches for different genetic subtypes.
- FLT3 mutation targeted therapies
- Novel chemotherapy combinations
- Treatment strategies for adult AML
Myelodysplastic Syndromes
Investigates treatments for both higher-risk and lower-risk myelodysplastic syndromes. Specializes in developing therapies for anemia management and exploring novel therapeutic agents for disease control.
- RARA-positive MDS treatments
- Anemia management strategies
- Advanced hematologic malignancies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.